Sofinnova Ventures β Full Portfolio
211 tracked investments Β· page 1 of 2 Β· listed companies and verified rows first
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)Dov Goldstein(Executive Officer)
BoardPatrick Enright(Director)in
Board seatJames HealyΒ· per SEC Form D
Co-investorsAndreessen HorowitzElad GilFelicis VenturesIA Seed VenturesLongitude CapitalOrbiMed+4 more
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)
Board seatDavid KabakoffΒ· per SEC Form D
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+2 more
Seaport Therapeutics develops therapeutics and medicines.
BiotechMental HealthBoston, US
Daphne Zohar(Founder, CEO and Board Member)inMichael Chen(Executive Officer)Lana Gladstein(Executive Officer)Antony Loebel(Executive Officer)Eric Green(Executive Officer)
Board seatJames I. HealyΒ· per SEC Form D
Co-investorsARCH Venture PartnersForesite CapitalHAWKTAILPureTech Health
Developing innovative biologic therapeutics with transformative clinical potential.
South San Francisco, US
Board seatMaha KatabiΒ· per SEC Form D
Co-investorsAbingworthKleiner Perkins
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)
Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalForesite CapitalRA CapitalSofinnova Venture Partners+1 more
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapeutics for central nervous system disorders, including Alzheimer's disease, Rett syndrome, and Fragile X syndrome.
BiotechHealthtechPortola Valley, US
Alexandre Vamvakides(Executive Officer)Axel Paeger(Board Member (founder))Harvey Lalach(Executive Officer, Director)George Tidmarsh(Executive Officer, Director)Terrie Kellmeyer(Interim Chief Executive Officer)Christopher U. Missling(Executive)
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Frederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Co-investorsCardinal PartnersEcoR1 CapitalDomain PartnersPolaris PartnersSamsara BioCapital
Bolt Biotherapeutics develops cancer immunotherapies that use the innate immune system to help the body recognize and eliminate tumor cells.
Co-investorsPfizer Venture InvestmentsRA CapitalSamsara BioCapitalVivo CapitalNan Fung Life SciencesNovo Holdings+1 more
Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.
BiotechHealthtechMedical DevicesRedwood City, US
Dennis M. Lanfear(Executive Officer, Director)Denny Lanfear(Founder)inAlan C. Herman(Executive Officer)Jean-Frederic Viret, Ph.D.(Executive Officer)Peter K. Watler, Ph.D.(Executive Officer)Barbara K Finck, M.D.(Executive Officer)
Co-investorsF-Prime CapitalHEALTHCARE ROYALTY PARTNERSVenrock
Editas Medicine develops gene-editing medicines using CRISPR technology to treat serious genetic diseases.
BiotechMedical DevicesCambridge, US
Katrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)Alexandra Glucksmann(Executive Officer)Douglas Cole(Director)Kevin Bitterman(Director)Andrew Hack(Executive Officer)
Co-investorsEcoR1 Capital
Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need.
Biotech
Clinical-stage biopharma developing therapies for debilitating diseases with unmet need.
BiotechHamilton
RICHARD S LEVY(Director)STEPHEN R BIGGAR(Director)FELIX J BAKER(Director)THOMAS W BEETHAM(Executive Officer)SANJ K PATEL(Executive Officer, Director)THOMAS R MALLEY(Director)
BiotechLa Jolla, US
Brook Byers(Co-founder)inMATTHEW W. FOEHR(Director)JOHN L. HIGGINS(Executive Officer, Director)MATTHEW KORENBERG(Director)CHARLES S. BERKMAN(Director)
BoardDAVID M. KNOTT(Director)
Co-investorsVenrock
Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.
BiotechDigital HealthHealthtechMedical Devices
Matthew Rabinowitz(Co-founder & Executive Chairman)Jonathan Sheena(Founder)in
Co-investorsBain Capital Life SciencesCheyenne VenturesClaremont Creek VenturesForesite CapitalHarmony PartnersLightspeed Venture Partners+1 more
Hugh Griffith(Founder)in
Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins.
BiotechDun Laoghaire, Co. Dublin, US
Tran B. Nguyen(Executive Officer)Arthur W. Homan(Executive Officer)Karin L. Walker(Executive Officer)Tara Nickerson, Ph.D.(Executive Officer)Wagner M. Zago, Ph.D.(Executive Officer)Carol D. Karp(Executive Officer)
Rapport is a biopharmaceutical company developing novel therapeutics.
BiotechHealthtechMedical Devices
Abe Ceesay(President)Cheryl GaultDr. Sevigny
Co-investorsARCH Venture Partners
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Matthew Henn(President and Chief Scientific Officer)
Co-investorsFlagship PioneeringRA Capital
BiotechWaltham, US
John Pallies(Executive Officer)Arlene Morris(Executive Officer, Director)
BoardDennis Podlesak(Director)Ivor Royston(Director)Luke Evnin, Ph.D.(Director)Kim Kamdar, Ph.D(Director)
Co-investorsForesite CapitalPappas CapitalvenBio Partners
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Bharatt Chowrira(Executive Officer)Michael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)Paul Miller(Executive Officer)Aoife Brennan(Executive Officer)Todd Shegog(Executive Officer)
Co-investorsAtlas VentureNew Enterprise Associates (NEA)NSG VenturesPfizer Venture InvestmentsSolasta VenturesOrbiMed
Aledia develops next-generation MicroLED display technology based on 3D nanowires grown on silicon, operating a pilot line and high-volume production facility.
Deep TechHardwareSemiconductorsGrenoble, FR
philippe GILET(Founder)in
Co-investorsBraemar Energy VenturesIntel CapitalDemeterIngka InvestmentsSupernovaTEL Venture Capital, Inc.+3 more
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)
Co-investorsvenBio PartnersMRL Ventures FundCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso Ventures+7 more
Expedition Therapeutics develops oral small-molecule treatments for inflammatory and respiratory diseases, with lead candidate EXPD-101, a once-daily DPP1 inhibitor for chronic obstructive pulmonary disease (COPD).
BiotechHealthtechSan Francisco, US
Co-investorsForbionNovo HoldingsSanofi Ventures
BiotechGaithersburg, US
Gregory L. Merril(Executive Officer, Director, Promoter)Carl R. Merril(Executive Officer, Director)
BoardEvan Loh(Director)Jana Jensen(Director)Raymond L. Martz(Director)
Board seatJonathan LeffΒ· per SEC Form D Β· $30M raise Β· filed Jun 2023
Co-investorsAMR Action Fund
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Davis Ryman(Executive Officer)Micah Zajic(Executive Officer)Ian Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatLars EkmanΒ· per SEC Form D
Co-investorsCoastCapCTI Life Sciences Fund L.P.FJ LabsvenBio PartnersvenBio Global Strategic
Developing drugs for rare cardiopulmonary disease.
Boston, US
Board seatMaha KatabiJonathan LeffΒ· per SEC Form D
Co-investorsAtlas Venture
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)Gail Maderis(Director)Kristine Ball(Executive Officer, Director)Elaine Chien(Executive Officer)Sarah Walter(Executive Officer)Raju Gadiraju(Executive Officer)
Board seatDavid KabakoffΒ· per SEC Form D
Co-investorsAdjuvant CapitalBrace PharmaCanaan PartnersLumira VenturesMPM BioImpactOUP (Osage University Partners)+3 more
Developing therapeutics for autoimmune and inflammatory diseases.
Crestwood, US
Board seatMaha KatabiΒ· per SEC Form D
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Board seatJames HealyΒ· per SEC Form D
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHongShan Capital GroupLAVLilly Asia Ventures+2 more
Durham, US
Board seatChris CarpenterJames HealyΒ· per SEC Form D Β· $150M raise Β· filed Apr 2025
Pleasanton, US
Chih-Ping Liu(Executive Officer, Director, Promoter)
BoardEdgar G Engleman(Director)
Board seatJames HealyΒ· per SEC Form D
Co-investorsVivo Capital
BiotechCleveland, US
Arnon Chait(Executive Officer, Director)ANDREW SUMMERS(Executive Officer)
BoardJOSEPH RICH(Director)SAMEER ROHATGI(Director)DARA WRIGHT(Director)
Board seatNoel JeeΒ· per SEC Form D Β· $14.4M raise Β· filed Oct 2025
Co-investorsJobsOhio VenturesJumpstart VenturesLYFE Capital
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Board seatMaha KatabiΒ· per SEC Form D Β· $56M raise Β· filed Feb 2016
Co-investorsAstellas Venture Management LLCMission Bay CapitalMission BiocapitalOUP (Osage University Partners)Pfizer Venture InvestmentsUS Venture Partners
Boston, US
Board seatNoel JeeΒ· per SEC Form D Β· $112.3M raise Β· filed Oct 2024
Co-investorsSR One Capital Management
Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.
BiotechHealthtechSan Diego, US
Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)
BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)
Board seatJonathan LeffΒ· per SEC Form D Β· $189.2M raise Β· filed Oct 2023
Co-investorsNorwest Venture PartnersRiverVest Venture Partners
BiotechStevenage, Hertfordshire
Ian Pitfield(Executive Officer)David Fellows(Director)Jessica Stitt(Executive Officer)Renee Gala(Director)Khurem Farooq(Executive Officer)Edward Lang(Executive Officer)
Board seatMaha KatabiΒ· per SEC Form D Β· $148M raise Β· filed Apr 2021
Co-investorsForbion
San Francisco, US
Board seatMaha KatabiΒ· per SEC Form D Β· $160.4M raise Β· filed Jun 2024
Co-investorsvenBio Partners
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)Ying Huang(Director)Derek Metzger(Executive Officer)
BoardPerry Nisen(Executive Officer, Director)Maria Fardis(Director)
Board seatMaha KatabiΒ· per SEC Form D
Co-investorsLongitude CapitalVida VenturesBiotechnology Value FundFrazier Life Sciences
Seattle, US
Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)Joseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)
BoardRobert Shepler(Director)in
Board seatDavid KabakoffΒ· per SEC Form D Β· $35.7M raise Β· filed Jul 2023
Co-investors5AM VenturesArboretum VenturesF-Prime CapitalTelegraph Hill Partners
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Board seatMaha KatabiΒ· per SEC Form D
Co-investorsSamsara BioCapitalScion Life SciencesTCG CrossovervenBio PartnersVersant VenturesVivo Capital+1 more
Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment.
BiotechHardwareHealthtechMedical DevicesSan Mateo, US
Dr. Chou(Founder & Chief Executive Officer)Cindy Lynch(Executive Officer)Tony Chou(Executive Officer, Director)in
BoardJack Lasersohn(Director)inTamir Meiri(Director)Jonathan Root(Director)in
Board seatNoel JeeΒ· per SEC Form D Β· $50M raise Β· filed Apr 2026
Co-investorsNorwest Venture PartnersRunway Growth CapitalUS Venture PartnersThe Vertical Group
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inJason Hafler(Director)Nancy Stagliano(Director)Michelle Carpenter(Executive Officer)Matthew Fust(Director)Amrit Nagpal(Director)
Board seatMaha KatabiΒ· per SEC Form D
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesAgent CapitalBlue Owl Capital+8 more
A pharmaceutical company that develops medicines and vaccines for patients globally.
BiotechHealthtechMedical DevicesCambridge, US
WYLIE W. VALE(Director)JOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)KEVIN F. MCLAUGHLIN(Executive Officer)MATTHEW L. SHERMAN(Executive Officer)
Co-investorsBessemer Venture PartnersForesite CapitalLightstone VenturesLowercarbon CapitalVenrockCollaborative Fund
Co-investors5AM VenturesFrazier Life Sciences
Focused on developing drugs, including for NASH and metabolic/inflammatory/fibrotic diseases.
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
DAVID GRYSKA(Director)VICENTE ANIDO(Executive Officer, Director)MURRAY GOLDBERG(Director)ANAND MEHRA(Director)BRIAN LEVY(Executive Officer)GERALD CAGLE(Director)
Co-investorsAlta PartnersAvoro Capital AdvisorsForesite CapitalOUP (Osage University Partners)
BiotechHealthtech
BiotechCincinnati, US
Joseph H. Gardner(Executive Officer)Robert Shalwitz(Executive Officer)Joseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)
AFYX is a biopharmaceutical company focused on reformulation and repurposing of existing pharmaceuticals for conditions including head and neck cancer, labor induction, cluster headaches, and pain and addiction.
BiotechHealthtechMedical DevicesHΓΈrsholm, DK
Dr. Claus J. MΓΈller-San Pedro(CEO)
Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtech
Co-investorsBain Capital Life SciencesRA Capital
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Co-investors5AM VenturesEcoR1 CapitalNew Enterprise Associates (NEA)RA CapitalCowen Healthcare InvestmentsFidelity Investments+1 more
BiotechHealthtechMedical Devices
Co-investorsNew Enterprise Associates (NEA)
Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Carlos Quezada-Ruiz(Chief Medical Officer)
Co-investorsBain Capital Life SciencesTCG Crossover
Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.
BiotechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsFountain Healthcare PartnersLongitude CapitalSignet Healthcare Partners
Co-investorsBioBritKeiretsu Forum
Developing broad-spectrum antifungal agents for invasive fungal infections.
BiotechSan Diego, US
Mitchell Mutz(Executive Officer, Director)
BoardChrysa Mineo(Director)Jack Florio(Director)Elaine Heron(Director)Santosh Vetticaden(Director)Karen Talmadge(Director)
Co-investorsNew Enterprise Associates (NEA)Pappas CapitalRiverVest Venture PartnersSofinnova Venture Partners
Anesiva is a biopharmaceutical company developing Nexletol for diet management.
Biotech
Anthera produces makeup and skincare products made in France with natural, non-toxic ingredients that are cruelty-free and vegan.
ConsumerWellness & FitnessFrance, FR
Co-investorsVantagePoint Capital Partners
Developing products for diseases associated with inflammation.
BiotechHayward, US
May Liu(Executive Officer)
Co-investorsPappas Capital
Apeiron Therapeutics is a biotech company developing small-molecule therapeutics with a focus on immuno-oncology and oncology drug discovery.
AI & Machine LearningBiotechDeep TechHealthtechBurlingame, US
Mingxi Li(CEO)Fred Aswad(Chief Scientific Officer)
Co-investorsPanacea Venture
Co-investorsAvoro Capital AdvisorsEpidarex CapitalF-Prime CapitalKeyhorse CapitalSolasta VenturesvenBio Partners
Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.
BiotechDeep TechHealthtechLongevity
Nils Regge(Co-Founder & General Partner)in
Co-investorsBLN CapitalCoastCapFJ LabsKfW CapitalTruVenturo GmbHCTI Life Sciences Fund L.P.+3 more
BiotechVancouver
Andrew I. Koven(Executive Officer)Eric L. Trachtenberg(Executive Officer)Scott J. Charles(Executive Officer)Kenneth B. Lee Jr.(Director)Arthur S. Kirsch(Director)Adrian Adams(Executive Officer, Director)
Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.
Biotech
Juan Jaen(Founder)in
Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalForesite CapitalSLVC+2 more
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan MΓΈller Mikkelsen(Founder, President and Chief Executive Officer)James Healy(Director)Grethe Rasmussen(Executive Officer)Harald Rau(Executive Officer)Rafa?le Tordjman(Director)Martin Olin(Director)
Co-investorsVivo CapitalAisling CapitalAvoro Capital AdvisorsForesite CapitalRA Capital
A biotechnology company developing new therapies for patients with high unmet medical needs.
Biotech
Co-investorsDolby Family Ventures
Advancing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases.
BiotechMedical Devices
Co-investorsLightstone VenturesHatteras Venture Partners
Co-investorsAisling Capital
Co-investorsKurma Partners
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
Biotech
Athena Countouriotis(Co-Founder, Chief Executive Officer)
Co-investorsDelos CapitalForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMed+3 more
New gene therapy treatments for people with serious, rare diseases.
BiotechBannockburn, US
James L'Italien(Executive Officer)Andrew F. Knudten(Executive Officer)Paul Manning(Director)Sukumar Nagendran(Executive Officer)Bong Koh(Director)Thomas Dee(Executive Officer)
Co-investorsForesite CapitalPBM CapitalRA Capital
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical DevicesSan Diego, US
Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)Ramin Farzaneh-Far(Executive Officer)Justin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)
Co-investorsPfizer Venture InvestmentsRA CapitalVida Ventures
Co-investorsAvoro Capital AdvisorsNew Enterprise Associates (NEA)
Activating the immune system to recognize and destroy tumor cells.
BiotechCambridge, US
Art Krieg(Executive Officer, Director)Barry Labinger(Executive Officer, Director)Chuck Abdalian(Executive Officer)David Mauro(Executive Officer)Karen Brennan(Executive Officer)Charles Yon(Executive Officer)
Co-investorsF-Prime CapitalLongitude CapitalNovo Holdings
Co-investorsLongitude Capital
BiotechNewton Centre, US
Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)
BoardScott Minick(Director)Todd T. Foley(Director)inVincent Miles(Director)Ansbert K. Gadicke(Director)in
Co-investorsHEALTHCARE ROYALTY PARTNERSMPM BioImpact
Co-investors5AM Ventures
Advancing clinical candidates for cardiovascular, metabolic and kidney diseases.
BiotechCincinnati, US
Marc de Garidel(Executive Officer, Director)
Co-investorsSofinnova Partners
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)
Co-investorsAN Venture PartnersARCH Venture PartnersCasdin CapitalFidelity InvestmentsInvusRock Springs Capital
BiotechChelsea, US
RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)MARK IWICKI(Executive Officer, Director)MARTIN FREED(Executive Officer)
BoardROB HOPFNER(Director)
Co-investorsCanaan PartnersBay City CapitalLongitude CapitalOrbiMedRA Capital
Claris Bio is a late-stage therapeutics company developing pharmacologic treatments for sight-threatening ophthalmic conditions with no or limited treatment options.
BiotechHealthtech
Co-investorsRA CapitalNovo Holdings
BiotechJersey City, US
Henry Rath(Executive Officer)Susan Orr(Executive Officer)Clarke Atwell(Executive Officer, Director)Stephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)
Co-investorsCatalio Capital ManagementNovo HoldingsSamsara BioCapital
Received FDA approval for Tracleer to treat pulmonary arterial hypertension.
Co-investorsAlta PartnersFrazier Life Sciences
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)
Co-investorsLongwood FundBAM ElevateFinchley Healthcare VenturesForbionLuma GroupNovo Holdings+1 more
DealForma is a curated biopharma deals database offering licensing deal comps, M&A data, company and drug pipeline profiles, funding rounds, and Tableau-based interactive dashboards with natural-language search.
BiotechData & InfrastructureHealthtech
Co-investorsTinySeedAlgerRA CapitalREDMILERTW Investments L.P.
Hospital-based therapies for acute, life-threatening neurological conditions.
BiotechBerkeley Heights, US
Robert Loch Macdonald(Executive Officer, Director)Brian A. Leuthner(Executive Officer, Director)Andrew Einhorn(Executive Officer)Albert N. Marchio II(Executive Officer)Herbert J. Faleck(Executive Officer)
BoardIsaac Blech(Director)
Co-investorsBioBrit
Antibacterials to treat serious drug-resistant bacterial infections.
HealthtechPlymouth, US
John K. Bakewell(Director)Brian E. Farley(Director)Shawn T McCormick(Director)David B. Milne(Director)Douglas Rohlen(Director)Stephen R. Paidosh(Executive Officer)
Forty Seven Inc was a clinical-stage immuno-oncology company developing antibody therapies targeting CD47, a "don't eat me" signal exploited by cancer cells, with lead candidate magrolimab.
BiotechHealthtechPalo Alto, US
Christopher Schaepe(Director)Dennis Henner(Director)Ravindra Majeti(Director)Eric Jensen(Executive Officer)Irving Weissman(Director)
BoardJeffrey Bird(Director)
Co-investorsBluebird VenturesLightspeed Venture Partners
Galera Therapeutics is a biotechnology company developing antibody-based and other therapeutics.
BiotechHealthtechMedical DevicesMalvern, US
Mel Sorensen(Executive Officer, Director)Joel Sussman(Executive Officer)Jeffery L. Keene(Executive Officer)Dennis P. Riley(Executive Officer)Jon T. Holmlund(Executive Officer)Robert A. Beardsley(Executive Officer, Director)
Co-investorsNew Enterprise Associates (NEA)
BiotechEmeryville, US
Andrew Allen(Executive Officer, Director)Vassiliki Economides(Executive Officer)Matthew Hawryluk(Executive Officer)Shefali Agarwal(Director)Elaine Jones(Director)Naiyer A. Rizvi(Director)
Co-investorsFrazier Life SciencesREDMILE
The site at this domain is a consumer guide to online casinos in Florida, publishing reviews, rankings, and explanations of gambling laws, bonuses, payment methods, and responsible play.
Media & EntertainmentSan Mateo, US
Anukool Lakhina(Executive Officer, Director)
BoardJose Suarez(Director)Amit Shah(Director)Brian Wilcove(Director)Andrew Fligel(Director)Michael LaJoie(Director)
Co-investorsTransLink CapitalArtiman VenturesGoldman SachsIntel CapitalQuestMark PartnersSingTel Innov8 Pte Ltd.
Co-investorsCambridge Innovation Capital
ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.
BiotechHealthtechMedical DevicesOslo, NO
Roy Larsen(Scientific Founder)Γyvind Bruland(Scientific Founder)Jonathan Freeman(Interim CEO)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)
Co-investorsB Capital GroupB4 CapitalF-Prime CapitalAlexandriaB CapitalQatar Investment Authority+1 more
HealthtechWaltham, US
Adam Gridley(Executive Officer, Director)Peter Greenleaf(Executive Officer, Director)
BoardJoshua Baltzell(Director)Kevin Rakin(Director)Garheng Kong, M.D., Ph.D.(Director)Garheng Kong, M.D., Ph.D(Director)
Co-investorsFOUNDATION MEDICAL PARTNERSSplit Rock Partners
Addressing unmet needs in gastroenterology and hepatology.
BiotechBrisbane, US
Bo Jesper Hansen(Director)Christine Nash(Executive Officer)Natalie Holles(Executive Officer)Jake R. Nunn(Director)Bijan Salehizadeh(Director)Daniel G. Welch(Director)
Co-investorsBay City Capital
Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.
BiotechDigital HealthMedical DevicesBrisbane, US
Rangachari Narasimhan(Executive Officer, Director)Grace Colon(Executive Officer, Director)Miller Samantha(Executive Officer)Carlos A. Schuler(Executive Officer, Director)John S. Patton(Executive Officer, Director)
BoardMcCarthy Reenie(Director)
Co-investorsAsset Management CompanyHealthCapDeerfield Management Company
Co-investorsFountain Healthcare Partners
BiotechBoston, US
Axel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)
BoardEdward Mathers(Director)Rob Hopfner(Director)Martin Edwards(Director)
Co-investorsLongitude CapitalNew Enterprise Associates (NEA)Sanofi VenturesPivotal Life Sciences
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Michael W. Dunne(Executive Officer, Promoter)Corey N. Fishman(Executive Officer, Director, Promoter)Judith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)
BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)
Co-investorsBay City CapitalCanaan PartnersFrazier Life SciencesSofinnova Venture Partners
PureTech Founded Entity that developed KarXT (Cobenfy) for schizophrenia and was acquired by Bristol Myers Squibb for $14 billion.
Co-investorsPureTech Health
Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.
Co-investorsARCH Venture Partners
Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.
Advanced ManufacturingBiotechHealthtechMedical Devices
Co-investorsARCH Venture PartnersCross Creek AdvisorsPfizer Venture InvestmentsSignet Healthcare Partners
Co-investorsAlpha Wave GlobalvenBio Partners
BiotechRadnor, US
Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)
BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesCanaan PartnersConnecticut InnovationsDomain AssociatesFlare Capital Partners+1 more
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.
BiotechMedical DevicesUtrecht, NL
Ton Logtenberg(Executive Officer, Director)Mark Throsby(Executive Officer)Hui Liu(Executive Officer)John Crowley(Executive Officer)L. Andres Sirulnik(Executive Officer)Lex Bakker(Executive Officer)
Co-investorsAvoro Capital AdvisorsPfizer Venture InvestmentsRA Capital
HealthtechNew Orleans, US
Mark Heiman(Executive Officer)Dale Pfost(Executive Officer, Director, Promoter)
BoardDon Marvin(Director)Richard Montgomery(Director)Ross Barrett(Director)John Elstrott(Director, Promoter)
Co-investorsBayern KapitalDCVC (Data Collective)FemHealth VenturesPangaea Ventures
Co-investors1315 CapitalSV Health Investors
Molecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX.
BiotechAustin, US
Co-investorsLongitude CapitalSolasta Ventures
Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
BiotechEvanston, US
Joseph R. Moskal(Executive Officer)Amin Khan(Executive Officer)James Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)
Co-investorsCota CapitalEcoR1 CapitalLatterell Venture Partners
BiotechCambridge, US
Richard Gaynor, M.D.(Executive Officer)Robert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)Eric Lander(Director)Hugh Dowd(Executive Officer, Director)
BoardCary Pfeffer, M.D.(Director)
Co-investorsNextech InvestClal Biotechnology IndustriesThird Rock Ventures
BiotechGrand Prairie, US
Steven Lutz(VP Sales)Carolyn Sikes(VP Clinical Affairs)Russ McMahen(VP Research and Development)Margaret Cabano(VP Operations)Richard Eisenstadt(Chief Financial Officer and Secretary)Asif Mughal(VP Quality Assurance)
Developing a novel treatment for acute muscle spasms.
BiotechSan Diego, US
Kathleen D. Scott(Chief Financial Officer, Secretary and Treasurer)Judy Caron(Chief Operating Officer)David F. Hale(Chairman of the Board of Directors, Acting President and CEO)Brian Dorsey(Director)Daniel Becker(Director)Joshua Richardson(Director)
Co-investorsH.I.G. HealthBridge PartnersLongitude Capital
Medical DevicesNew Jersey, US
Co-investorsBay City CapitalF-Prime Capital
NorthSea Therapeutics is a late-stage clinical biotechnology company developing structurally engineered fatty acids (SEFAs) as oral treatments for metabolic, cholestatic, and fibrotic diseases.
BiotechHealthtech
Co-investorsNew Science VenturesvenBio PartnersYsios Capital
Nurix Therapeutics develops targeted protein degradation medicines, including degrader-antibody conjugates (DACs), designed to eliminate disease-causing proteins using the cell's natural degradation machinery.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Arthur T. Sands(Executive Officer, Director)Timothy Kutzkey(Executive Officer, Director)
BoardDavid Goeddel(Director)Mark Goldsmith(Director)
Co-investorsBain Capital Life SciencesEcoR1 CapitalForesite CapitalThe Column Group
The page is a Vietnamese-language sports streaming site (90Phut TV / 90Phutr.tv, also called Vaoroi TV) offering free live football streaming links, match schedules, standings, results, news, and betting odds.
Media & EntertainmentSports TechHΓ Nα»i, VN
Co-investorsAisling CapitalM VenturesNew Enterprise Associates (NEA)Sofinnova Partners
Ocular is a clinical-stage biopharmaceutical company developing AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel, aimed at reducing the treatment burden of retinal diseases.
BiotechHealthtechMedical DevicesBedford, US
W. James O'Shea(Director)Kevin Hanley(Executive Officer)Richard L. Lindstrom(Director)Michael Goldstein(Executive Officer)Amarpreet Sawhney(Director)Daniel Bollag(Executive Officer)
Co-investorsAscension VenturesSV Health InvestorsTop Corner CapitalAgent Capital
OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.
BiotechMedical DevicesNew York, US
Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)
Co-investorsOrbiMedCatalio Capital Management, LPF-Prime CapitalInsight PartnersNVIDIA
BiotechNew York, US
David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)
Co-investorsSV Health InvestorsClarusSV Life Sciences
Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.
BiotechHealthtechLa Jolla, US
Preston Klassen(Executive Officer)Joseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)
BoardEckard Weber(Director)Brian H. Dovey(Director)in
Co-investorsCross Creek AdvisorsNew Enterprise Associates (NEA)Domain AssociatesDomain Partners
Perception Neuroscience is a clinical-stage biotech developing R-ketamine (PCN-101), a single-isomer glutamatergic modulator being studied as a rapid-acting antidepressant for patients with treatment-resistant depression.
BiotechDigital HealthHealthtechMental Health
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)Leon Chen, Ph.D.(Director)Carol Gallagher(Director)Joshua Resnick, M.D.(Director)
BoardMichael Powell(Director)
Co-investorsMission Bay CapitalMission BiocapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova Venture Partners
Co-investorsSofinnova Partners
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)
BoardPETER THOMPSON(Director)SRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsAccess BiotechnologyMission BiocapitalMission Bay CapitalNew Leaf Venture PartnersOrbiMedSamsara BioCapital
Co-investorsHEALTHCARE ROYALTY PARTNERS
BiotechMalvern, US
Mark Lupher(Executive Officer)Dominick C. Colangelo(Executive Officer, Director)
BoardJames W. Broderick, M.D.(Director)Geert-Jan Mulder(Director)John Friedman(Director)Harold R. Werner(Director)
Co-investorsEaston CapitalEaston Capital Investment GroupForbion
Co-investorsF-Prime CapitalNew Enterprise Associates (NEA)
Pharmaceutical company acquired by Biogen
Co-investorsFrazier Life SciencesKern Capital, LLC
Discovery and development of drugs to address behavioral disorders.
BiotechRockville, US
Kristian Humer(Director)Christopher Gerry(Executive Officer, Director)Anand Kiran Parikh(Executive Officer, Director)Josiah Craver(Executive Officer)
BoardBob Holmen(Director)Phillip B. Donenberg(Director)
BiotechLa Jolla, US
Allison E. Hulme(Executive Officer, Director)Randall E. Woods(Executive Officer, Director)Peter T. Slover(Executive Officer)Gerald T Proehl(Director)John E Geltosky(Director)Jim E. Heppell(Director)
One-time gene therapy products including a candidate for RPE65-related blindness.
BiotechPhiladelphia, US
Joseph W. La Barge(Executive Officer)Elliott Sigal(Director)Rogerio Vivaldi(Director)Arthur Dantchik(Director)Lars Ekman, M.D. Ph.D.(Director)Steven M. Altschuler(Director)
Spark Therapeutics, now part of the Roche Group, focuses on delivering therapies to improve patient outcomes and create healthier communities.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsFountain Healthcare Partners
Co-investorsBain Capital Life Sciences
BiotechOmaha, US
Paul Kinnon(Executive Officer, Director)Leon F. Richards(Executive Officer)ANTONIUS P SCHUH(Director)CRAIG J TUTTLE(DIRECTOR, PRESIDENT AND CEO)CHAD M RICHARDS(CHIEF COMMERCIAL OFFICER)BRETT L FREVERT(CFO)
RNA therapeutics; NASDAQ TBIO, acquired by Sanofi.
Co-investorsM VenturesMRL Ventures Fund
Co-investorsKleiner PerkinsRidgeback Capital
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.